PT-141 (Bremelanotide): A Melanocortin Receptor Agonist

What PT-141 is

PT-141, whose international name is bremelanotide, is a small synthetic peptide: a cyclic heptapeptide (seven amino acids in a ring structure) derived from and analogous to α-MSH, the alpha-melanocyte-stimulating hormone. It functions as a non-selective melanocortin receptor agonist, with primary activity at MC4R and additional activity at MC1R and MC3R.

It is administered subcutaneously. Its most distinctive feature, compared with other compounds aimed at the same therapeutic target, is that its mechanism is central — it acts within the nervous system, not on peripheral blood flow.

The melanocortin system (MC1R–MC5R) and why MC4R matters

Melanocortins are a family of signaling peptides (α-MSH among them) that act on five G-protein-coupled receptors, designated MC1R through MC5R. Each subtype has a different distribution and function:

• MC1R — expressed on melanocytes; regulates skin and hair pigmentation.
• MC2R — the ACTH receptor in the adrenal cortex; endocrine axis.
• MC3R — present in the central nervous system; involved in energy balance.
• MC4R — concentrated in the hypothalamus; a central axis for appetite control and several neurobehavioral signals.
• MC5R — linked to exocrine glands.

The MC4R is the receptor of greatest interest for PT-141 because it is located in the hypothalamic melanocortin pathways. It is through activation of these central circuits that bremelanotide exerts its effect, in contrast to compounds that act in the periphery.

Central action vs vascular agents (the key mechanistic difference)

The most important distinction for understanding PT-141 is where it acts. There are two completely different mechanistic strategies:

• PDE5 inhibitors — act on the peripheral vascular system, modulating phosphodiesterase type 5 and local blood flow.
• PT-141 (bremelanotide) — acts centrally, on the melanocortin pathways of the nervous system (hypothalamus, via MC4R). It is not a vascular agent.

This difference is fundamental: PT-141 does not operate by the same route as PDE5 inhibitors. Its mechanism is neurological and originates in the brain, making it a distinct object of study within melanocortin pharmacology.

Clinical & research context

Bremelanotide has a documented clinical history. As a clinical fact: bremelanotide was approved by the FDA in 2019 under the trade name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. This is cited here purely as a regulatory fact about the compound, not as an indication for use.

Beyond that milestone, scientific interest in PT-141 centers on its role as a tool to study melanocortin signaling and the neurobehavioral circuits of the central nervous system. The material we offer is investigational in nature; this guide is educational and does not constitute medical advice.

PT-141 vs MT-2 (same melanocortin family, different targets)

PT-141 and MT-2 (Melanotan II) belong to the same class of melanocortin agonists and share a structural origin in α-MSH. However, the focus of study for each is different:

Both activate melanocortin receptors, but MT-2 is studied mainly for its action on pigmentation (the MC1R axis), while interest in PT-141 revolves around its central activity at MC4R.

Reconstitution

PT-141 is supplied as a lyophilized powder in a 10 mg vial, reconstituted with your own bacteriostatic water at the concentration you define.

Calculation example (10 mg vial + 2 mL bacteriostatic water = 5 mg/mL): to research 0.5 mg → 0.1 mL → 10 units on a U100 syringe.

Refrigerate (2–8 °C) after reconstitution. For custom calculations use the reconstitution calculator or see the complete reconstitution guide.

PT-141 at Renova

PT-141 is available in a 10 mg vial, as lyophilized powder, at $115.

Our material is manufactured in a cGMP-compliant US lab that we work with directly, with a Certificate of Analysis (COA) by HPLC and mass spectrometry.